Galera Therapeutics is executing a pivotal strategic transformation anchored by an all-stock merger agreement with Obsidian Therapeutics and the acquisition of Nova Pharmaceuticals, signaling a new growth trajectory. The company has divested its primary clinical-stage antioxidant assets, avasopasem and rucosopasem, to Biossil Inc., suspending prior development programs. These moves position Galera to leverage combined biopharmaceutical platforms post-merger while maintaining operational liquidity. However, execution risks remain elevated amid ongoing integration challenges and regulatory uncertainties.